- Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012 - Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: TPI287; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Not yet recruiting - verified April 2012 - Conditions: Patients Must Have Histologically or Cytologically Confirmed Non-squamous Cell, Non Small Cell Carcinoma of the Lung.; Patient Must Have Measurable Stage IV Disease (Includes M1a, M1b Stages or Recurrent Disease).
Interventions: Drug: Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Drug: Paclictaxl, Carboplatin, and Bevcizumab.
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Conditions: Radiation Retinopathy; Macular Edema
Interventions: Drug: Aflibercept every 2 months; Drug: Aflibercept monthly
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Regeneron Pharmaceuticals
Not yet recruiting - verified April 2012 - Conditions: Glioblastoma; Glioblastoma Multiforme
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Not yet recruiting - verified May 2012 - Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Valproic Acid; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Recurrent Glioma
Interventions: Drug: Bevacizumab; Drug: Minocycline; Radiation: Radiation
Sponsors: University of Utah; University of Utah
Not yet recruiting - verified April 2012 - Condition: Stage IIIC Ovarian Cancer
Interventions: Biological: FANG™ Vaccine; Drug: Bevacizumab
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012 - Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified April 2012 - Condition: Age Related Macular Degeneration
Intervention: Drug: aflibercept 2.0 mg
Sponsors: Greater Houston Retina Research; David M. Brown, M.D.; Regeneron Pharmaceuticals
Recruiting - verified February 2012 - Condition: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: Academic and Community Cancer Research United; Academic and Community Cancer Research United
Not yet recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: FOLFOX + bevacizumab; Dietary Supplement: Vitamin D; Dietary Supplement: Vitamin D
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified April 2012 - Conditions: Neoplasms; Cancer
Interventions: Drug: VGX-100; Drug: Bevacizumab
Sponsors: Circadian Technologies Ltd.; Circadian Technologies Ltd.
Recruiting - verified March 2012 - Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: Propranolol; Drug: Chemotherapy; Procedure: Surgery; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Conditions: Neuroblastoma; Sarcoma
Intervention: Drug: Cyclophosphamide, Topotecan, and Bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Children's Mercy Hospital Kansas City; Penn State University; University of Colorado Health Sciences Center and The Children's Hospital; Johns Hopkins Medical Center Sidney Kimmel Comprehensive Cancer Center; Phoenix Children's Hospital Center for Cancer & Blood Disorders; Alberta Children's Hospital; MD Anderson Cancer Center Orlando; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Conditions: Melanoma; Metastatic Melanoma
Interventions: Drug: Vemurafenib; Drug: Bevacizumab
Sponsors: Melanoma Research Foundation Breakthrough Consortium; Melanoma Research Foundation Breakthrough Consortium; Genentech
Not yet recruiting - verified April 2012 - Condition: Proliferative Diabetic Retinopathy
Interventions: Other: Prompt Panretinal Photocoagulation; Drug: 0.5-mg Ranibizumab; Other: Deferred panretinal photocoagulation
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Diabetic Macular Edema
Intervention: Drug: Macugen (Pegaptanib Sodium)
Sponsors: Retina Institute of Hawaii; Retina Institute of Hawaii; Eyetech Pharmaceuticals
Available - verified December 2011 - Conditions: Exudative Macular Degeneration; Diabetic Macular Edema
Interventions: Drug: Avastin; Drug: Avastin; Drug: Lucentis
Sponsors: Vitreo-Retinal Associates, Michigan; Vitreo-Retinal Associates, Michigan; Van Andel Research Institute
Recruiting - verified November 2011 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving BevacizumabConditions: Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Macular Edema
Interventions: Drug: ranibizumab 0.5mg; Drug: ranibizumab 1.0mg
Sponsors: Hanscom, Thomas, M.D.; Hanscom, Thomas, M.D.; Genentech
Recruiting - verified November 2011 - Conditions: Glioma; Glioblastoma; Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Drug: VAL-083
Sponsors: Del Mar Pharmaceuticals (BC), LTD; Del Mar Pharmaceuticals (BC), LTD
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: Axitinib; Drug: Bevacizumab; Drug: 5-FU; Drug: 5-FU; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified January 2012 - Condition: Glioblastoma Multiforme
Intervention: Drug: Avastin
Sponsors: Brain & Spine Surgeons of New York; Brain & Spine Surgeons of New York
Recruiting - verified February 2012 - Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab; Drug: Ranibizumab
Sponsors: Vitreo-Retinal Associates, PC; Vitreo-Retinal Associates, PC; Genentech
Recruiting - verified January 2012 - Condition: Colorectal Cancer, Metastatic
Interventions: Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay; Other: Standard of care
Sponsors: Myriad Genetic Laboratories, Inc.; Myriad Genetic Laboratories, Inc.
Recruiting - verified February 2012 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: Ozurdex; Drug: Ozurdex
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Condition: Solid Tumors
Interventions: Drug: Bevacizumab; Drug: Dasatinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Intervention: Drug: Temozolomide, bevacizumab and bortezomib
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: Intravitreal injection of bevacizumab; Drug: Intravitreal injection of ranibizumab (0.5 mg per dose)
Sponsors: Barnes Retina Institute; Barnes Retina Institute; Retina Associates of Florida, P.A.; Illinois Retina Associates; Kresge Eye Institute; Long Island Vitreoretinal Consultants; Mid Atlantic Retina; Retina Associates, Kansas City; Massachusetts Eye and Ear Infirmary
Recruiting - verified February 2012 - Condition: Rectal Cancer Patients
Intervention: Other: Bevacizumab 5 mg/kg
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified August 2011 - Condition: Colorectal Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: Placebo; Drug: bevacizumab [Avastin]; Drug: FOLFOX regimen; Drug: leucovorin; Drug: 5-FU
Sponsors: Genentech; Genentech; Sarah Cannon Research Institute
Recruiting - verified January 2012 - Conditions: Glioblastoma; Brain Neoplasm
Intervention: Procedure: Craniotomy
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012 - Conditions: Telangiectasia, Hereditary Hemorrhagic; Epistaxis
Interventions: Drug: Sterile saline; Drug: Bevacizumab; Drug: Estriol; Drug: Tranexamic Acid
Sponsors: Georgia Health Sciences University; James Gossage; Hereditary Hemorrhagic Telangiectasia Foundation International
Recruiting - verified February 2012 - Condition: Keloid
Intervention: Biological: bevacizumab
Sponsors: Tirgan, Michael H., M.D.; Tirgan, Michael H., M.D.
Recruiting - verified February 2012 - Condition: HIGH GRADE GLIOMA
Interventions: Drug: TH-302; Drug: Placebo
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals; The University of Texas Health Science Center at San Antonio
Recruiting - verified July 2011 - Condition: Renal Cell Carcinoma
Intervention: Drug: everolimus and bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Drug: Submucosal Bevacizumab
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified July 2011 - Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Drug: Bevacizumab
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified July 2011 - Conditions: Brain Cancer; MALIGNANT GLIOMA; Glioblastoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Anaplastic Oligo-astrocytoma (AOA); Anaplastic Mixed Gliomas; Malignant Glioma NOS
Intervention: Other: Bevacizumab & stereotactic radiotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Columbia University; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: FOLFIRI-bevacizumab regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Drug: BIBF 1120
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Boehringer Ingelheim Pharmaceuticals; Wake Forest University Baptist Medical Center; Dartmouth-Hitchcock Medical Center; University of Virginia; Massachusetts General Hospital
Not yet recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Interventions: Drug: Bevacizumab and Carboplatin; Drug: Bevacizumab and Carboplatin
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified December 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Colorectal Adenocarcinoma
Interventions: Drug: Brivanib; Drug: Irinotecan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: pemetrexed disodium
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Glioblastoma Multiforme
Interventions: Drug: Bevacizumab; Drug: BKM120
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Novartis
Recruiting - verified March 2012 - Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012 - Conditions: High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor; Drug: Plerixafor; Drug: Bevacizumab; Drug: Plerixafor; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genzyme
Recruiting - verified February 2012 - Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: capecitabine; Drug: GDC-0980; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Condition: Colon Cancer
Interventions: Drug: chemotherapy and GI-4000; Drug: GI-4000
Sponsors: Georgetown University; Georgetown University; GlobeImmune
Recruiting - verified February 2012 - Conditions: Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer
Interventions: Drug: oxaliplatin; Drug: leucovorin calcium; Drug: fluorouracil; Biological: bevacizumab; Procedure: therapeutic conventional surgery; Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A; Other: laboratory biomarker analysis; Other: pharmacological study; Drug: irinotecan hydrochloride
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Biological: OC-DC vaccine; Drug: Bevacizumab; Drug: cyclophosphamide 300 mg/m2/d for 3 days; Drug: fludarabine 30 mg/m2/d for 3 days; Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Conditions: Brain Tumor; Spinal Tumor; Glial Tumour of Brain; Ependymal Tumour of Brain; Spinal Cord Ependymoma; Anaplastic Ependymoma
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: BKM-120 Bevacizumab
Sponsors: Dana-Farber Cancer Institute; Toni Choueiri, MD; Beth Israel Deaconess Medical Center
Recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: irinotecan hydrochloride; Biological: bevacizumab; Biological: cetuximab; Drug: capecitabine; Genetic: mutation analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: nucleic acid sequencing; Genetic: protein expression analysis; Genetic: polymerase chain reaction; Genetic: DNA analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012 - Condition: Brain Cancer
Interventions: Drug: Vorinostat; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Interventions: Drug: Bevacizumab; Drug: Bevacizumab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Bevacizumab; Drug: Cetuximab; Drug: Cixutumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eli Lilly and Company; Genentech; ImClone LLC
Recruiting - verified May 2012 - Condition: Lung Cancer
Intervention: Drug: Pazopanib
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Condition: Neoplasms
Interventions: Drug: EZN-2208; Drug: Bevacizumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2010 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011 - Condition: Advanced Solid Tumors
Interventions: Drug: MEDI3617; Drug: MEDI3617 - Dose Expansion (CRC); Drug: MEDI3617 - Dose Expansion (NSCLC); Drug: MEDI3617 Single-Agent Optional Dose Expansion; Drug: MEDI3617 + Bev Q3W Dose Escalation; Drug: MEDI3617 + Bev Q2W Dose Escalation; Drug: MEDI3617 + Bev Optional Dose Expansion; Drug: MEDI3617 + Weekly Pax Dose Escalation; Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc; Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012 - Conditions: Macular Edema; Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Peripheral Laser
Sponsors: Retina Associates of Florida, P.A.; Retina Associates of Florida, P.A.
Recruiting - verified November 2011 - Conditions: Choroidal Neovascularization; Myopia; Punctate Inner Choroidopathy (PIC); Multifocal Choroiditis; Ocular Histoplasmosis Syndrome; Central Serous Chorioretinopathy (CSC); Angioid Streaks; Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.); Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Interventions: Drug: Ozurdex; Drug: Avastin
Sponsors: Long Island Vitreoretinal Consultants; Long Island Vitreoretinal Consultants
Recruiting - verified April 2012 - Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tubes Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified February 2012 - Condition: Glioma
Intervention: Drug: Crenolanib (CP-868,596)
Sponsors: Arog Pharmaceuticals LLC; Arog Pharmaceuticals LLC
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Bevacizumab; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Advanced Cancers
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: 24GyE proton and Anti-VEGF; Drug: 16GyE and anti-VEGF; Drug: Sham Irradiation and anti-VEGF
Sponsors: University of California, Davis; University of California, Davis; University of California, San Francisco
Recruiting - verified November 2011 - Conditions: Esophageal Carcinoma; GE Junction Cancer
Intervention: Drug: bevacizumab + FOLFOX
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified March 2012 - Conditions: Rectal Cancer; Colon Cancer; Metastasis; Adenocarcinoma
Interventions: Drug: Hydroxychloroquine; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil; Drug: 5-fluorouracil; Drug: Bevacizumab
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance; Celgene Corporation
Recruiting - verified December 2011 - Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Gastrointestinal Cancers
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012 - CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerConditions: Esophageal Cancer; Gastric Cancer
Interventions: Drug: bevacizumab; Drug: trastuzumab; Drug: oxaliplatin; Drug: capecitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genentech
Recruiting - verified September 2011 - Conditions: Sarcoma; Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Sorafenib; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Glioblastoma Multiforme; Gliosarcoma
Intervention: Drug: Gliadel, Radiation Therapy, Avastin, Temodar
Sponsors: Duke University; Duke University; Genentech; Eisai Inc.
Recruiting - verified March 2012 - Condition: Advanced Cancers
Interventions: Drug: Lenalidomide; Drug: Bevacizumab; Drug: Sorafenib; Drug: Temsirolimus; Drug: Lenalidomide; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012 - Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; University of California, San Francisco; Children's Hospital Boston; Children's Memorial Hospital; Children's Hospital Los Angeles; University of Utah; Memorial Sloan-Kettering Cancer Center; Seattle Children's Hospital; Children's Hospital Colorad; Doernbecher Children's Hospital; Washington University Children's Hospital; Miami Children's Hospital; Johns Hopkins University; University of Florida; Children's Hospitals and Clinics of Minnesota; Southwestern Regional Medical Center; New York University; University of Rochester; University of Mississippi Medical Center; Louisville Children's Hospital; Children's Healthcare of Atlanta
Recruiting - verified September 2011 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: FOLFIRI, Avastin, Irinotecan
Sponsors: University of Chicago; University of Chicago; National Institute for Cancer Research, Italy
Recruiting - verified June 2011 - Condition: Liver Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech; OSI Pharmaceuticals
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Diarrhea; Neutropenia
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Advanced Cancer
Interventions: Drug: Bendamustine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cephalon; National Comprehensive Cancer Network
Recruiting - verified March 2012 - Conditions: Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: DNA methylation analysis
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Genentech
Recruiting - verified February 2012 - Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: MINT1526A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Conditions: HLRCC; Metastatic Papillary RCC
Interventions: Drug: Bevacizumab; Drug: Erlotinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Glioma
Interventions: Drug: E7080; Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors: Columbia University; Columbia University; Genentech
Recruiting - verified October 2011 - Conditions: Chemotherapy; Tumor; Ovarian Cancer
Intervention: Biological: OCDC
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Acoustic Schwannoma; Adult Anaplastic Meningioma; Adult Ependymoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Meningeal Hemangiopericytoma; Adult Papillary Meningioma; Neurofibromatosis Type 1; Neurofibromatosis Type 2; Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012 - Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified April 2012 - Condition: Advanced Cancer
Interventions: Drug: Nab-paclitaxel; Drug: Bevacizumab; Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Grade IV Malignant Glioma; Glioblastoma Multiforme; Gliosarcoma
Intervention: Drug: AMG 102 plus Avastin (bevacizumab)
Sponsors: Duke University; Duke University; Amgen
Recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Glioblastoma; GBM; Glioblastoma Multiforme
Intervention: Drug: PF-00299804
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Henry Ford Hospital; Pfizer
Recruiting - verified April 2012 - Condition: Brain Cancer
Intervention: Drug: Temozolomide, bevacizumab, lithium, radiation
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech; Ohio State University; Atlantic Health System
Recruiting - verified February 2012 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified January 2012 - Conditions: Sarcoma; Soft Tissue Sarcoma; Locally Advanced Sarcoma; Unresectable Sarcoma; Metastatic Sarcoma
Intervention: Drug: Bevacizumab, Gemcitabine, docetaxel and valproic acid
Sponsors: University of Iowa; University of Iowa; Genentech
Recruiting - verified June 2011 - Condition: Glioblastoma Multiforme
Intervention: Drug: Bevacizumab
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; Genentech
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Drug: Irinotecan and Bevacizumab
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech
Recruiting - verified March 2012 - Conditions: Glioblastoma; Gliosarcoma; Brain Tumor
Interventions: Radiation: radiosurgery; Biological: bevacizumab; Drug: irinotecan hydrochloride
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Vestibular Schwannoma
Intervention: Drug: Bevacizumab (Avastin)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified September 2011 - Conditions: Prostate Cancer; Metastatic Castrate Resistant Prostate Cancer
Intervention: Drug: TRC105
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Corneal Neovascularization
Interventions: Drug: Avastin (bevacizumab); Drug: 0.9% NaCl & Refresh Liquigel
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Conditions: Brain Cancer; Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab; Drug: Low Dose Bevacizumab; Drug: Lomustine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Advanced Non-squamous Non-Small Cell Lung Cancer
Interventions: Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg; Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg
Sponsors: University of Chicago; University of Chicago; Genentech
Recruiting - verified June 2011 - Condition: Carcinoma
Interventions: Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin; Drug: Intraperitoneal Oxaliplatin
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified December 2011 - Condition: Advanced Cancers
Interventions: Drug: HAI Abraxane; Drug: Gemcitabine; Drug: Bevacizumab; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Hemangiosarcoma; Soft Tissue Sarcoma
Intervention: Drug: Paclitaxel in combination with Bevacizumab
Sponsors: Stanford University; Stanford University; Genentech
Recruiting - verified February 2012 - Condition: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: ixabepilone; Drug: bevacizumab
Sponsors: Providence Health & Services; Providence Health & Services; Genentech; Bristol-Myers Squibb
Recruiting - verified July 2011 - Condition: Colorectal Cancer
Interventions: Drug: RAD011; Drug: FOLFOX; Drug: Bevacizumab
Sponsors: University of Utah; University of Utah; Novartis
Recruiting - verified January 2012 - Condition: Advanced Cancer
Interventions: Drug: Dasatinib; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cholangiocarcinoma
Intervention: Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Genentech
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: XELOX regimen; Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Pemetrexed, Cisplatin, Bevacizumab
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Refractory Solid Tumors in Children
Intervention: Drug: combination of Irinotecan, vincristine, temozolomide and bevacizumab
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified October 2009 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Liver Cancer; Advanced Cancer
Interventions: Drug: Irinotecan; Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0941; Drug: paclitaxel; Drug: pemetrexed; Drug: cisplatin
Sponsors: Genentech; Genentech
Recruiting - verified November 2011 - Condition: Head and Neck Cancer
Intervention: Other: bevacizumab, cisplatin, cetuximab, radiation therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified January 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0941; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Malignant Glioma
Intervention: Drug: bevacizumab and CPT-11 and Carboplatin
Sponsors: Duke University; Duke University
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: trastuzumab; Drug: carboplatin; Drug: docetaxel; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Prostate Cancer
Interventions: Drug: Bevacizumab; Drug: Lenalidomide; Drug: Docetaxel; Drug: Prednisone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Advanced Cancers
Interventions: Drug: HAI Oxaliplatin; Drug: 5-FU; Drug: Bevacizumab; Drug: Cetuximab; Drug: Leucovorin; Drug: 5-FU; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Testicular Cancer
Interventions: Drug: Bevacizumab; Drug: Gemcitabine; Drug: Docetaxel; Drug: Melphalan; Drug: Carboplatin; Drug: Mesna; Drug: Ifosfamide; Drug: Etoposide; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Advanced Non-small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012 - Condition: Colon Cancer With Metastases to the Liver
Interventions: Device: LC bead loaded with Irinotecan; Drug: FOLFOX6 and Avastin
Sponsors: University of Louisville; University of Louisville; Biocompatibles UK Ltd
Recruiting - verified November 2011 - Condition: Renal Cell Carcinoma
Interventions: Drug: Bevacizumab; Drug: Azacitidine
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011 - Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin; Drug: Bevacizumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Renal Cell Carcinoma
Interventions: Drug: Bevacizumab; Drug: Ixempra (Ixbepilone [BMS-247550]
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: DC vaccine; Drug: Bevacizumab; Biological: IL-2; Biological: IFN
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Pulmonary Veno Occlusive Disease
Intervention: Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
Sponsors: Children's Hospital Boston; Children's Hospital Boston
Recruiting - verified June 2011 - Conditions: Newly Diagnosed High-Grade Gliomas; Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Temozolomide; Drug: Bevacizumab; Drug: Irinotecan
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; Genentech
Recruiting - verified February 2012 - Conditions: Sarcoma; Leiomyosarcoma; Malignant Fibrous; Histiocytoma; Angiosarcoma
Intervention: Drug: gemcitabine and docetaxel with bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified February 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Brain Cancer; Pediatric Cancers
Interventions: Drug: Bevacizumab; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified March 2012 - Conditions: Recurrent Glioblastoma Multiforme; Recurrent Gliosarcoma
Intervention: Drug: temozolomide and bevacizumab
Sponsors: Center for Neurosciences, Tucson; Center for Neurosciences, Tucson; Genentech
Recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine; Procedure: adjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Duke University; Duke University; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified June 2010 - Conditions: Glial Cell Tumors; Malignant Gliomas; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliomatosis Cerebri; Gliosarcoma; Brainstem Glioma
Interventions: Drug: Valproic acid; Drug: Bevacizumab; Radiation: Radiation therapy
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified February 2012 - Condition: Central Nervous System Tumors
Interventions: Drug: Bevacizumab; Drug: Irinotecan; Drug: Temozolomide
Sponsors: All Children's Hospital; All Children's Hospital; V Foundation
Recruiting - verified June 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Imprime PGG® Injection; Biological: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Biothera; Biothera
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: ursodiol; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: positron emission tomography (PET)
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Malignant Glioma
Interventions: Drug: LBH589; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Brigham and Women's Hospital; Massachusetts General Hospital; Northwestern University; University of Virginia; Genentech; Novartis
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: pentostatin
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Melanoma
Interventions: Drug: Bevacizumab Plus Ipilimumab; Drug: Bevacizumab Plus Ipilimumab; Drug: Bevacizumab Plus Ipilimumab; Drug: Bevacizumab Plus Ipilimumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Solid Tumor
Interventions: Drug: Bevacizumab; Drug: Temozolomide; Drug: Vincristine sulfate; Drug: Irinotecan; Drug: Cefixime or Cefpodoxime
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012 - Conditions: Stomach Cancer; Gastric (Stomach) Cancer; Neoplasm of Cardioesophageal Junction; Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: capecitabine
Sponsors: Stanford University; Pamela L. Kunz; Genentech
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy; Drug: bicalutamide; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Cancer Institute of New Jersey
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Celgene Corporation; Genentech
Recruiting - verified February 2012 - Condition: Brain Neoplasms
Intervention: Drug: Ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); AMAG Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Recurrent or Refractory Solid Tumors; CNS Malignancies
Interventions: Drug: Bevacizumab; Drug: Everolimus
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Biological: bevacizumab; Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Hodgkin Lymphoma
Intervention: Drug: Avastin
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech
Recruiting - verified November 2011 - Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Drug: Bevacizumab; Drug: Cetuximab; Drug: Pemetrexed; Radiation: Radiation therapy
Sponsors: University of Pittsburgh; University of Pittsburgh; Eli Lilly and Company; Genentech
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel; Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Sponsors: Penn State University; Penn State University
Recruiting - verified July 2011 - Conditions: Osteosarcoma; Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Biological: Bevacizumab; Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genentech; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Conditions: Refractory Solid Tumors; Leukemia
Interventions: Drug: Bevacizumab; Drug: Sorafenib; Drug: Cyclophosphamide
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ABI-007l albumin-stabilized nanoparticle formulation
Sponsors: Loyola University; Loyola University; Genentech
Recruiting - verified September 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel; Drug: Gemcitabine; Biological: Avastin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Genentech
Recruiting - verified August 2011 - Condition: Brain Cancer
Intervention: Drug: Palonosetron (Aloxi) and Dexamethasone
Sponsors: Duke University; Duke University; Eisai Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Capecitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Doxil; Drug: Carboplatin; Drug: Bevacizumab
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified October 2011 - Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified May 2012 - Condition: Recurrent Glioblastoma
Interventions: Drug: enzastaurin; Drug: bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Genentech
Recruiting - verified October 2011 - Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Advanced Cancer
Interventions: Drug: Bevacizumab; Drug: Sorafenib; Drug: Erlotinib; Drug: Trastuzumab; Drug: Lapatinib; Drug: Sunitinib; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Advanced Cancer
Interventions: Drug: Valproic Acid; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Peritoneal Cancer
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Abraxane; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Duke University; Duke University; Genentech
Recruiting - verified June 2011 - Conditions: Esophageal Neoplasms; Stomach Neoplasms; Neoplasm Metastasis
Intervention: Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors: Duke University; Duke University; Hoffmann-La Roche; Sanofi-Aventis; Genentech
Recruiting - verified December 2011 - Condition: Peritoneal Cancer
Interventions: Drug: Sorafenib; Biological: Bevacizumab; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Procedure: dynamic contract-enhanced magnetic resonance imaging; Procedure: needle biopsy; Procedure: positron emission tomography; Radiation: fludeoxyglucose F 18
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab; Drug: Bevacizumab; Drug: Docetaxel
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Genentech; Case Comprehensive Cancer Center; University of Pittsburgh
Recruiting - verified April 2012 - Conditions: Advanced Malignancy; Lymphoma; Myeloma; Solid Tumors
Interventions: Drug: Bevacizumab; Drug: Bortezomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012 - Condition: Renal Cell Cancer
Interventions: Drug: Bevacizumab and Bortezomib; Drug: Bevacizumab and Bortezomib
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012
 |
Bevacizumab Clinical Trials |
